THERESA TUCKMANTEL GIBBS

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner BOONE, NC NPI 1497271365

General Payments — all program years on this page

$1,580.21

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 96
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $302.39 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $288.9217
Entertainment $13.471

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
ABBVIE INC. $140.389
Medtronic, Inc. $44.352
Acerta Pharma LLC $36.262
Actelion Pharmaceuticals US, Inc. $19.101
GlaxoSmithKline, LLC. $19.041
Novo Nordisk AS $15.351
SHIELD THERAPEUTICS INC $14.441
OPTOS, INC. $13.471

By program year

Program yearAmountRecords
2021 $512.6933
2022 $557.9734
2023 $207.1611
2024 $302.3918

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1078896813 Actelion Pharmaceuticals US, Inc. $19.10 07/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100452814 Novo Nordisk Inc $15.35 03/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104205395 AstraZeneca Pharmaceuticals LP $18.21 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105493977 AstraZeneca Pharmaceuticals LP $18.05 05/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168021 ABBVIE INC. $12.47 03/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168023 ABBVIE INC. $12.73 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168025 ABBVIE INC. $14.55 06/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168027 ABBVIE INC. $21.10 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168029 ABBVIE INC. $14.19 09/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168031 ABBVIE INC. $11.01 09/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168033 ABBVIE INC. $18.59 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168035 ABBVIE INC. $17.35 11/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107168037 ABBVIE INC. $18.39 12/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116638220 GlaxoSmithKline, LLC. $19.04 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116954796 Medtronic, Inc. $21.38 01/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116954798 Medtronic, Inc. $22.97 03/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141506390 Optos, Inc. $13.47 01/18/2024 Entertainment Undisputed 01/23/2026 View at CMS
1150155670 SHIELD THERAPEUTICS INC $14.44 11/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.